Pluri, a biotechnology company, has obtained patents in the US and Israel for its immune cell expansion technologies focusing on mucosal-associated invariant T (MAIT) cells. These cells show promise in treating solid tumors with reduced risks of side effects, offering significant advantages over traditional T cells.